Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Community Regional Cancer Center
mi
from
Indianapolis, IN
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Arnett Cancer Care
mi
from
Lafayette, IN
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Arnett Cancer Care
mi
from
Lafayette, IN
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Horizon Oncology Center
mi
from
Lafayette, IN
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Methodist Cancer Center
mi
from
Omaha, NE
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/13/2016
Oncology Partners Network, Ltd.
mi
from
Cincinnati, OH
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/13/2016
Oncology Partners Network, Ltd.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BATTLE Program: Sorafenib in Patients With NSCLC
A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/13/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
BATTLE Program: Sorafenib in Patients With NSCLC
A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/13/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Clinical Trial for CTD-ILD Treatment
Clinical Trial of Oral Medication for CTD-ILD Treatment
Status: Enrolling
Updated:  1/14/2016
University of Michigan
mi
from
Ann Arbor, MI
A Clinical Trial for CTD-ILD Treatment
Clinical Trial of Oral Medication for CTD-ILD Treatment
Status: Enrolling
Updated: 1/14/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
Click here to add this to my saved trials
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Reirradiation Registry Study
Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy
Status: Enrolling
Updated:  1/20/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Reirradiation Registry Study
Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy
Status: Enrolling
Updated: 1/20/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  1/20/2016
Moores Cancer Center
mi
from
La Jolla, CA
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 1/20/2016
Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  1/20/2016
Yale University
mi
from
New Haven, CT
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 1/20/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  1/20/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 1/20/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
UAB Cancer Center
mi
from
Birmingham, AL
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
UAB Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
California Cancer Center
mi
from
Encinitas, CA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
California Cancer Center
mi
from
Encinitas, CA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
California Cancer Center Associates
mi
from
Fresno, CA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
California Cancer Center Associates
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
UCLA-Department of Medicine a Division of Hem/Onc
mi
from
Los Angeles, CA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
UCLA-Department of Medicine a Division of Hem/Onc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
VA Eastern Colorado Healthcare System
mi
from
Denver, CO
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
VA Eastern Colorado Healthcare System
mi
from
Denver, CO
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Christiana Care Health Services, Inc
mi
from
Newark, DE
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Cancer Specialists of North Florida - CBO
mi
from
Jacksonville Beach, FL
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Cancer Specialists of North Florida - CBO
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
AMPM Research
mi
from
Miami, FL
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
AMPM Research
mi
from
Miami, FL
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Research Medical Center
mi
from
Kansas City, KA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Research Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Ochsner Clinical Foundation
mi
from
New Orleans, LA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Ochsner Clinical Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
St. Joseph Mercy Ann Arbor Cancer Center
mi
from
Ann Arbor, MI
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
St. Joseph Mercy Ann Arbor Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Montefire-Einstein Center for Cancer Care
mi
from
Bronx, NY
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Montefire-Einstein Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Clinical Research Alliance
mi
from
New York, NY
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Clinical Research Alliance
mi
from
New York, NY
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Durham VA Medical Center
mi
from
Durham, NC
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
W.G. (Bill) Hefner VA Medical Center
mi
from
Salisbury, NC
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
W.G. (Bill) Hefner VA Medical Center
mi
from
Salisbury, NC
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Dorn VA Medical Center
mi
from
Columbia, SC
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Dorn VA Medical Center
mi
from
Columbia, SC
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Regional Cancer Care Institute at Regional Health
mi
from
Rapid City, SD
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Regional Cancer Care Institute at Regional Health
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Associates in Oncology and Hematology
mi
from
Chattanooga, TN
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Associates in Oncology and Hematology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
San Antonio Military Medical Center
mi
from
Fort Sam Houston, TX
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
San Antonio Military Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Oncology Consultants
mi
from
Houston, TX
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Oncology Consultants
mi
from
Houston, TX
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Millennium Oncology
mi
from
Houston, TX
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Millennium Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/20/2016
Fpr Belvoir Community Hospital
mi
from
Fort Belvoir, VA
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/20/2016
Fpr Belvoir Community Hospital
mi
from
Fort Belvoir, VA
Click here to add this to my saved trials